Human IgG1/Immunoglobulin Heavy Constant Gamma 1 Rabbit Polyclonal Antibody for WB, ELISA - P01857

Core Product Specifications and Parameters

Biological Background: IGHG1 (Immunoglobulin Heavy Constant Gamma 1) Function and Localization

• Immunoglobulin heavy constant gamma 1 (IGHG1), also designated Ig gamma-1 chain C region, constitutes the constant domain of human IgG1 heavy chain. The UniProt canonical isoform has a calculated mass of 43,912 Da and is stabilized by intrachain disulfide bonds.
• In humoral immunity, membrane-bound IgG1 serves as the B-cell receptor (BCR); antigen binding initiates B-cell activation, clonal expansion, and differentiation into antibody-secreting plasma cells. Related references: PMID:17576170, PMID:20176268, PMID:22158414
• Secreted IgG1 antibodies block infection by preventing pathogen attachment via the variable domains and deploy constant-region guided effector mechanisms, including neutralization. Related references: PMID:17576170, PMID:20176268, PMID:22158414
• Antigen‑binding diversity is generated through V(D)J recombination, somatic hypermutation, and affinity maturation within germinal centers. Related references: PMID:17576170, PMID:20176268, PMID:22158414
• Class‑switch recombination replaces the μ/δ constant regions with γ1, thereby endowing IgG1 with distinct effector capabilities while retaining antigen specificity. Related references: PMID:17576170, PMID:20176268, PMID:22158414
• The Fc region of human IgG1 engages Fcγ receptors on phagocytes and NK cells (enabling antibody‑dependent cellular phagocytosis/ADCC) and C1q of the complement cascade (triggering CDC), thereby orchestrating pathogen clearance and inflammatory responses.
• IGHG1 transcripts can be alternatively spliced, and the protein undergoes N‑linked glycosylation; direct protein sequencing, proteomics identification, and 3D‑structure are noted in UniProt.
• Subcellular distribution encompasses soluble secretion and plasma membrane presentation (via a C‑terminal transmembrane helix) on B‑cell surfaces.

Experimental Guidance and Technical Tips

• The polyclonal antibody is raised against a recombinant immunogen spanning amino acids 21‑130 of human IgG1 (P01857), which contains the CH1 domain. Therefore, it is expected to recognize linear epitopes within the constant region; denaturing Western blot conditions should be feasible.
• For Western blotting, anticipate a band at approximately 44 kDa (reducing conditions) corresponding to the heavy chain. Consider using 4‑12% gradient gels and PVDF membrane for optimal transfer.
• The antibody demonstrates cross‑reactivity with mouse IgG, making it a candidate for assays involving mouse models or hybridoma screening. However, validation in the relevant sample matrix is advised.
• In ELISA applications, the polyclonal preparation may be employed as a coating or detection reagent. Titration and blocking against endogenous immunoglobulins in sera/plasma may be necessary.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio provides diagnostic manufacturers and researchers with a streamlined pathway to secure IVD raw materials. For immunoassay developers targeting human IgG subclasses, we offer a comprehensive portfolio of validated antibody pairs, including this IGHG1 polyclonal antibody, alongside matched monoclonal reagents, recombinant antigens, and bulk ancillary supplies. Our sourcing platform accelerates the transition from concept to clinic by consolidating rare‑target reagents and technical support under one roof.